The results of the RCTs and meta-analyses mentioned above appear to be inconsistent, which prompted us to investigate the cardiovascular benefits of SGLT2 inhibitors further and explore whether these therapies can also be used for the treatment of HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.